Logo-jre
Submitted: 04 Nov 2016
Accepted: 19 Dec 2016
ePublished: 06 Jan 2017
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Ren Endocrinol. 2017;3: e02.
  Abstract View: 2103
  PDF Download: 1482

Mini-Review

Administration of baclofen in end-stage renal disease

Fatemeh Hayati 1, Mohammad Amin Nasouti 1*, Shokhouh Shayanpour 1, Shahla Ahmadi Halili 1

1 Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
2 Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
*Corresponding Author: *Corresponding Author: Mohammad Amin Nasouti, , Email: moam790@dr.com

Abstract

Baclofen with chemical name of 4-amino-3-(-4-chlorophenyl)-butanoic acid is commonly used to treat dysfunctional voiding, intractable hiccups, palatal myoclonus and for alleviation of signs and symptoms of skeletal muscle spasticity and spasm. It is also currently used to treat trigeminal neuralgia, addiction to opiates, alcohol, or cocaine and for alleviation of pain among patients with multiple sclerosis or in patients with spinal or cerebral disorders. In individuals with disturbed kidney function and particularly in the patients with end-stage renal disease (ESRD), the accumulation of the drug is occurred and the half-life of the drug is prolonged which can lead to significant side effects and complication including neurological deterioration and coma.

Citation: Hayati F, Nasouti MA, Shayanpour S, Ahmadi Halili S, Nasouti A. Administration of baclofen in end-stage renal disease. J Renal Endocrinol. 2017;3:e02. DOI: 10.15171/jre.2017.02.

Implication for health policy/practice/research/medical education

In individuals with disturbed kidney function and particularly in the patients with end-stage renal disease (ESRD), the accumulation of the drug is occurred and the half-life of the drug is prolonged which can lead to significant side effects and complication including neurological deterioration and coma.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 2104

Your browser does not support the canvas element.


PDF Download: 1482

Your browser does not support the canvas element.